BioXcel Therapeutics Inc (BTAI)

Currency in USD
3.320
+0.350(+11.78%)
Closed·
Pre Market
3.200-0.120(-3.61%)
·
BTAI Scorecard
Full Analysis
RSI suggests the stock is in overbought territory
Unusual trading volume
BTAI is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.9803.840
52 wk Range
1.17015.456
Key Statistics
Prev. Close
3.32
Open
3.16
Day's Range
2.98-3.84
52 wk Range
1.17-15.456
Volume
49M
Average Volume (3m)
4.79M
1-Year Change
-78.45%
Book Value / Share
-16.44
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BTAI Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
19.000
Upside
+472.29%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week

BioXcel Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

BioXcel Therapeutics Inc Company Profile

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer’s disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia. The company has collaborations with Columbia University, Yale University Medical School, and University of North Carolina for the development of BXCL501. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Employees
37

Compare BTAI to Peers and Sector

Metrics to compare
BTAI
Peers
Sector
Relationship
P/E Ratio
−0.5x−1.1x−0.5x
PEG Ratio
−0.01−0.060.00
Price/Book
−0.2x2.2x2.6x
Price / LTM Sales
10.9x9.8x3.3x
Upside (Analyst Target)
141.0%303.2%43.5%
Fair Value Upside
Unlock20.0%6.9%Unlock

Analyst Ratings

3 Buy
1 Hold
1 Sell
Ratings:
5 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 19.000
(+472.29% Upside)

Earnings

Latest Release
May 12, 2025
EPS / Forecast
-1.50 / -0.21
Revenue / Forecast
168.00K / 400.00K
EPS Revisions
Last 90 days

BTAI Income Statement

People Also Watch

38.47
BMNR
+15.53%
2.310
UAVS
-6.85%
1.900
OPEN
-24.60%
5.50
REPL
-12.97%
6.5900
CYN
-4.91%

FAQ

What Stock Exchange Does BioXcel Therapeutics Trade On?

BioXcel Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for BioXcel Therapeutics?

The stock symbol for BioXcel Therapeutics is "BTAI."

What Is the BioXcel Therapeutics Market Cap?

As of today, BioXcel Therapeutics market cap is 20.11M.

What Is BioXcel Therapeutics's Earnings Per Share (TTM)?

The BioXcel Therapeutics EPS (TTM) is -12.28.

From a Technical Analysis Perspective, Is BTAI a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has BioXcel Therapeutics Stock Split?

BioXcel Therapeutics has split 1 times.

How Many Employees Does BioXcel Therapeutics Have?

BioXcel Therapeutics has 37 employees.

What is the current trading status of BioXcel Therapeutics (BTAI)?

As of 07 Aug 2025, BioXcel Therapeutics (BTAI) is trading at a price of 3.32, with a previous close of 3.32. The stock has fluctuated within a day range of 2.98 to 3.84, while its 52-week range spans from 1.17 to 15.46.

What Is BioXcel Therapeutics (BTAI) Price Target According to Analysts?

The average 12-month price target for BioXcel Therapeutics is USD19, with a high estimate of USD66 and a low estimate of USD1. 3 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +472.29% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.